A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture

Abstract

The effect of (+)-5-oxo-D-prolinepiperidinamide monohydrate (NS-105), a novel cognition enhancer, on adenylate cyclase activity was investigated in cultured neurons of the mouse cerebral cortex. NS-105 (10(-7) and 10(-6) M) inhibited forskolin-stimulated cyclic AMP formation, an action that was dependent on pertussis toxin-sensitive G proteins. Conversely, in pertussis toxin-pretreated neurons, NS-105 (10(-7)-10(-5) M) significantly enhanced the forskolin-stimulated cyclic AMP formation, and this action was completely reversed by cholera toxin. A metabotropic glutamate receptor agonist (1S, 3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S, 3R-ACPD) produced similar bi-directional actions on the cyclic AMP formation. Both of these inhibitory and facilitatory actions of NS-105 and 1S, 3R-ACPD were blocked by L(+)-2-amino-3-phosphopropinoic acid (L-AP3). NS-105 (10(-6) M) and 1S, 3R-ACPD (10(-4) M) significantly enhanced isoproterenol- and adenosine-stimulated cyclic AMP formation. The enhancement of such Gs-coupled receptor agonists-stimulated cyclic AMP formation was also produced by quisqualate but not by L(+)-2-amino-4-phosphonobutanoate (L-AP4). The phosphoinositides hydrolysis was enhanced by 1S, 3R-ACPD (10(-4) M) but not by NS-105 (10(-6) M), however, 1S, 3R-ACPD-induced increase in phosphoinositides turnover was attenuated by NS-105. These findings suggest that NS-105 stimulates metabotropic glutamate receptor subclasses that are coupled both negatively and positively to adenylate cyclase, but it acts as an antagonist at the receptor subclasses that are linked to phosphoinositides hydrolysis.

Attention-Deficit Hyperactivity Disorder and Pharmacotherapy—Past, Present, and Future: A Review of the Changing Landscape of Drug Therapy

“…66 Our group’s research in ADHD is focused on characterizing genetic variants that disrupt a specific pathway (the glutamatergic pathway) involving neurotransmission in the brain. We recently identified a small molecule compound, NFC-1, which previously underwent extensive clinical testing 67 and was shown to have stimulatory activity towards mGluR pathways, 68 –70 producing notable psychoactive effects in animal models. 71,72 The drug was originally developed in the late 1980s for treating dementia-related cognitive impairment but was eventually abandoned during phase III trials in dementia.…”

Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs

“…Fasoracetam significantly increased cAMP accumulation in membranes pretreated with pertussis toxin, indicating that it activates both inhibitory and stimulatory G proteins [107]. This effect seems to be mediated by GABA B receptors, but even cholinergic [108] and metabotropic glutamate [109] receptors have been found involved. No information is available on the influence of stereochemistry on nootropic activity of fasoracetam.…”

Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils

“…The content of cAMP in cells was measured according to the modified method of Oka et al (1997). Preparations of isolated neutrophils (10 6 cells/assay) were incubated at 37 8C in HBSS under the stream of gas mixture of 95% O 2 /5% CO 2 for 10 min.…”